European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Lymphoseek, tilmanocept, Date of authorisation: 19/11/2014, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 19 April 2024 - 15:15

Human medicines European public assessment report (EPAR): Lymphoseek, tilmanocept, Date of authorisation: 19/11/2014, Revision: 8, Status: Authorised

Paediatric Oncology Strategy Forum: 24-25 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 October 2024 to 25 October 2024

Submitted by Anonymous (not verified) on 19 April 2024 - 15:12

Paediatric Oncology Strategy Forum: 24-25 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 October 2024 to 25 October 2024

Product Management Service (PMS) Info-Day, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 April 2024, 09:15 (CEST) to 16 April 2024, 17:30 (CEST)

Submitted by Anonymous (not verified) on 19 April 2024 - 14:44

Product Management Service (PMS) Info-Day, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 April 2024, 09:15 (CEST) to 16 April 2024, 17:30 (CEST)

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 19 April 2024 - 14:35

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 19 April 2024 - 14:30

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 17, Status: Authorised

Industry Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRI, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 June 2024, 10:00 (CEST) to 13 June 2024, 11:30 (CEST)

Submitted by Anonymous (not verified) on 19 April 2024 - 14:25

Industry Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRI, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 June 2024, 10:00 (CEST) to 13 June 2024, 11:30 (CEST)

Network Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024, 10:00 (CEST) to 18 June 2024, 11:30 (CEST)

Submitted by Anonymous (not verified) on 19 April 2024 - 14:15

Network Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024, 10:00 (CEST) to 18 June 2024, 11:30 (CEST)

Veterinary medicines European public assessment report (EPAR): Respivac TRT, Turkey rhinotracheitis virus, strain 1062, live, Status: Opinion

Submitted by Anonymous (not verified) on 19 April 2024 - 14:12

Veterinary medicines European public assessment report (EPAR): Respivac TRT, Turkey rhinotracheitis virus, strain 1062, live, Status: Opinion

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness